Executive Summary

15.05.2018
  • Tatiana Golikova bound to work wonders in social sphere
  • CancerFund to support oncology R&D
  • Segregated liability to help decriminalize medical errors
  • While Roscomnadzor is after Telegram messenger, counterfeit drugs keep selling online
  • Vaccination to become a healthy lifestyle factor
  • Internet blocking discourages digital health investment
  • The path to long-term drug supply contracts runs through an obligation to invest
  • The reports of an FMCG retailer capturing the pharma market in the south of Russia are greatly exaggerated
  • A federal FMCG retailer to open pharmacies or drogeries in the Urals
  • Red tape and shortage of skilled personnel hamper cluster development
  • Strengths and weaknesses of contract manufacturing in Russia
  • Rating of Russian pharmacy chains, Q118
  • Russia considers extension of transition period for medical devices circulation in EAEU
  • Medical device approval procedure is still a challenge
  • Procedural procurement control stimulates negative selection
  • Imbalances in the medical devices circulation system
  • A comparative analysis of government procurement of infant incubators and phototherapy devices in Russia, Q1-316 – Q1-317
03.05.2018
  • Pharmacists asked not to be penalized for drug dispensing regulations violation until e-prescriptions are implemented
  • National Chamber for Pharmaceuticals drafts an appeal to President of Russia on inadmissibility of selling drugs at stores
  • Health insurers happy about their status quo
  • Pharmacy reputation no longer reflects its financial stability
  • Experts presented scenarios for pharma strategic development
  • Tracking a drug package will cost manufacturer 50 kopecks
  • Cancer care will not be able to do without co-funding
  • Is the situation with medical product manufacturing in Russia as bad as perceived by State Duma?
  • API imports to Russia, 2017
  • Government trastuzumab supply contracts, 2016—2017: a review
  • Anticoagulants market, 2015—2017: a review
  • Radiopharmaceutical manufacturing for Sverdlovsk Region to be localized at the Ural State University
26.04.2018
  • Collisions likely to be generated by anti-US legislative initiative
  • Pharma companies still interested in government subsidies
  • Pharma to propose solutions for protection of patent rights
  • Experts and officials discussed diversification of military production
  • A national cancer program yet to be developed
  • Kazan Apteki passed into the control of Aprel pharmacy chain
  • Pharmacy aggregators have both supporters and opponents
  • Drug manufacturers concerned about quality of integration of the regulator’s IT solutions
  • Shortage of cancer drugs in Russia’s regions forces patients to mass migration
  • Drug coverage system and cancer drug access: prospects
  • Russian manufacturers interested in access to foreign markets
  • Court upholds the regulator’s opinion on anti-competitive agreement of Udmurt Ministry of Health
  • Drug coverage beneficiaries to track their treatment status
  • Marketing unions go after Ural pharmacy chains
  • Specifics of zoo pharmacy development in Russia
  • The state shoulders the bulk of capital spending in healthcare
  • What hampers development of commercial services at public clinics?
  • Healthcare needs fundamental changes to extend life expectancy
24.04.2018
  • Fundamental changes in subsidized drug coverage have become imminent
  • EEC does not consider Russian labeling an obstacle for EAEU drug market
  • Nearly 9,000 insurance agents operate in Russia
  • Pharmacies may lose part of their product range because of supplement labeling
  • The number of cancer immunotherapeutics to grow
  • Federal Antimonopoly Service penalized a pharma company for an unregulated drug price
  • Local drug labeling equipment enters mass production
  • Moscow to implement a rotavirus immunization program
  • Russia short of laws and lab animals to implement biomedical technologies
  • Winners of Platinum Ounce’2017 award announced
  • Lack of e-document management procedure hampers telehealth
  • Wearable device data in demand by pharma companies
  • Insulin procurement contracts made in 2017: a review
  • A Bashkortostan pharmacy chain closed an acquisition deal
  • Battle for funding among drug developers intensifies
10.04.2018
  • Experts discuss priorities of Pharma-2030 Strategy
  • Pharmaceutical manufacturers may be forced to pay 5M-RUB fines for unreliable drug information
  • Vice-Premier Olga Golodets criticized government officials for inadequate registers of patients in need of pain management
  • Pharma companies practice huge price cuts
  • Manufacturer's prices must be the same for distributors and pharmacy chains
  • Moscow authorities to invite bidding for an offset agreement
  • Going to a new cancer management level requires concerted efforts
  • Main carrier of narcotic drugs suspended
  • State contracts to procure antibiotics, 2017: a review
  • Preferential Drug Coverage in Russia’s regions, 2017: a review
  • Preferential Drug Coverage, 2017: a review
  • Sverdlovsk pharmaceutical and medical manufacturers appraised new market opportunities
  • Innovative products require new regulatory approaches
  • Scientists explained why it takes long to implement medical R&D products
  • In 2017, Roszdravnadzor restricted sales of more than 1 million medical devices
  • Medical and health IT startups bound for a difficult path to telehealth
  • State purchasing of defibrillators, 2016—2017: a review
03.04.2018
  • FAS pledges of no double game
  • Analysts forecast pharmacy reduction in 2018
  • FAS suspicions in respect of MoH transpired just before formation of a new Russian government
  • Increasingly often, bidding front runners yield to outsiders
  • Market experts differ in their approaches to counterfeit drug control measures
  • Proposal to cancel MHI system voiced by chairperson of the Federation Council is likely to be president-approved
  • EEC offered a master class in clinical trials for pharma community
  • Rostech Center for Informatization to present an upgraded MHI GIS
  • Imports of finished and bulk medicinal products to Russia, 2017
  • Hospital segment of the Russian pharma market, 2017
  • Stavropol territorial government failed to terminate investment agreement with Escom
27.03.2018
  • A bill on upgrading penalties for corruption in drug procurement introduced to State Duma
  • Loopholes in law provide for unfair competition
  • Pharma-2030 Strategy to be introduced to Russian Government in June
  • Instable regulatory system still perceived as major market issue
  • Pharmacy chains switch over to quick-money agreements
  • Regulators challenge compliance with transportation regulations for investigational products
  • So far, Russia has failed to implement new innovative drug procurement models
  • Drug procurement by prevention and treatment facilities, 2017: a review
  • Drug procurement by healthcare providers, 2017: a review
  • Results of Pharma-Q Pharmacist Opinion survey, autumn 2017
  • Compounding pharmacies open in certain Russian regions
  • A federal pharmacy chain acquires two more regional players
  • A regional chain of PET/CT centers is gaining ground
20.03.2018
  • Pharma retailers size up a drogerie format
  • Nine billion rubles to be additionally allocated for orphan drug procurement in 2019
  • Small pharmacy chains may survive through uniting
  • ‘Georgian team’ quit Pharmacy Chain 36.6
  • Government guarantees in demand among pharmaceutical manufacturers
  • How is the pharmacy debt crisis to be resolved?
  • Experts discussed ‘informal’ physician–patient relationships
  • Government simplifies transportation regulations for narcotic drugs and psychotropic substances
  • Extension of List 24 requires amendments to law
  • Russian manufacturers fight for price advantages
  • Nonexistent EEC regulations on preclinical trials keep EAEU manufacturers on tenterhooks
  • EAEU members support common drug marking regulations but are not in a hurry to implement them
  • Unconventional approach in demand in TV drug adverts
  • Rating of pharmaceutical distributors, 2017 (IQVIA)
  • Rating of pharmaceutical distributors, 2017 (RNC Pharma)
  • Russian scientists still find it difficult to have their R&D products implemented
  • Fair competition is a solution
  • Russian regions seek for uncostly ways to extend the life of medical equipment
  • What the Russian medical industry expects from the government
  • Pharmacy sales of main medical device groups in 2017: a review
06.03.2018
  • Sberbank developed multi-resistance to innovative pharmaceutical projects
  • Pharma pricing reform delayed
  • Financial experts approved health expenditure growth
  • Kazakhstan accepted the first marketing applications to be executed in accordance with EAEU regulations
  • Experts discuss barriers to digital health development in Russia
  • Less than 50% state-of-the-art cancer drugs are available in Russia
  • Nativa continues trying originators’ patience
  • Artur Urazmanov never looks back
  • Biomedical project failures often relate to poor control
  • Russian presidential wannabes on healthcare-to-be
  • Experts consider pharmacy market over-heated
  • Doctors are offered AI to assign drugs
  • Rating of Russian pharmacy chains, 2017 (RNC Pharma)
  • Rating of Russian pharmacy chains and associations, 2017 (IQVIA)
  • Roszdravnadzor found equipment of questionable quality at private clinics
  • Pharmacies often fulfil the functions of outpatient clinics

27.02.2018
  • Pharmacy market consolidates to stand against food retailers
  • A new player will emerge on the pharma market that will set up its own rules
  • Budgets keep «dissolving» in medical digital space
  • Scientists seek ways for import substitution in nuclear medicine
  • Summing up Pharma-2020
  • The new pricing procedure to hurt more than just drug manufacturers
  • Drugs selling at food stores carry a threat nation-wide
  • Pharma wants to unite regulatory authorities
  • Pharmacy market, 2017: a report
  • Pharmaceutical advertising in specialized print media, Q1-317: a report
  • Cosmeceutical market, 2017: a report
  • Regional pharmacy chains complain about dumping practices of federal pharmaceutical retailers
  • Escom may be forced to pay for construction of pharmaceutical cluster infrastructure
  • Manufacturers aim at producing originator drugs and outqualifying imports
  • In Kazakhstan, beneficiary drug coverage problems relate to subjective root causes
Регистрируясь, вы принимаете условия
Пользовательского соглашения